Hanall Biopharma (009420) — Cash Flow-to-Debt Ratio
Hanall Biopharma (009420) has a Cash Flow-to-Debt Ratio of 0.17x as of September 2025, meaning its operating cash flow of ₩7.34 Billion could theoretically repay 0% of its total liabilities (₩44.17 Billion) in one year. See financial flexibility index of Hanall Biopharma to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hanall Biopharma Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for Hanall Biopharma across 14 annual periods. For the full cash flow conversion analysis, see how efficiently does Hanall Biopharma generate cash.
Annual Cash Flow-to-Debt Ratio for Hanall Biopharma (2011–2024)
Year-by-year debt coverage analysis for Hanall Biopharma. Check cash flow quality index of Hanall Biopharma to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.21x | ₩9.36 Billion | ₩44.53 Billion | ▼ -62.0% |
| 2023 | 0.55x | ₩29.64 Billion | ₩53.53 Billion | ▼ -0.7% |
| 2022 | 0.56x | ₩25.20 Billion | ₩45.19 Billion | ▲ +2223.1% |
| 2021 | 0.02x | ₩839.87 Million | ₩34.99 Billion | ▲ +0.4% |
| 2020 | 0.02x | ₩929.29 Million | ₩38.86 Billion | ▼ -94.1% |
| 2019 | 0.40x | ₩20.49 Billion | ₩50.97 Billion | ▲ +709.4% |
| 2018 | -0.07x | ₩-2.99 Billion | ₩45.39 Billion | ▼ -109.0% |
| 2017 | 0.73x | ₩42.14 Billion | ₩57.50 Billion | ▲ +278.0% |
| 2016 | 0.19x | ₩3.95 Billion | ₩20.37 Billion | ▲ +1035.7% |
| 2015 | -0.02x | ₩-454.02 Million | ₩21.91 Billion | ▲ +75.6% |
| 2014 | -0.09x | ₩-3.52 Billion | ₩41.36 Billion | ▲ +58.2% |
| 2013 | -0.20x | ₩-7.78 Billion | ₩38.23 Billion | ▼ -522.4% |
| 2012 | 0.05x | ₩2.20 Billion | ₩45.60 Billion | ▼ -64.4% |
| 2011 | 0.14x | ₩7.41 Billion | ₩54.75 Billion | — |